Chemotherapy induced febrile neutropenia (CIFN) is an adverse drug reaction which needs medical attention. The treatment options for CIFN are mandatory to improve treatment outcomes and quality of life. The aim of the study is to evaluate the incidence, causality, severity, preventability, predictability and to analyze the outcomes of CIFN in cancer patients.
A prospective observational study was conducted in the in-patients and out-patients of oncology department who received chemotherapy within the period of October 2016 to March 2017. The information such as demographics (age, gender, co-morbidities), complaints on admission, hematological investigations [neutrophil counts, platelet counts, hemoglobin levels, ESR, WBC], type of tumor, stage of cancer, prophylaxis, cycle of antineoplastic chemotherapy that cause FN, treatment history and outcome data were obtained from the patient’s clinical record. Multinational Association for Supportive Care in Cancer score and Absolute Neutrophil Count grading was used to predict the patient’s risk of developing CIFN.
Out of 200 patients, 19 patients developed 22 episodes of CIFN. The overall occurrence of CIFN during the study period was 9.5%. The higher incidence of CIFN has been observed among male gender (57.89%), age group between 45-60 years (52.63%), stage III patients (42.10%), solid tumor (73.68%) and double chemotherapy regimen (59.1%). The higher incidence of CIFN was developed in I cycle (36.36%) followed by II cycle (22.72%) and VI cycle (18.18%). The length of hospitalization has been prolonged for all patients who developed CIFN with 6 median numbers of days.
As per the WHO and Naranjo’s scales most of the CIFN reactions were classified as probable 81.82% and 77.2% respectively. Out of 22 CIFN cases, 9.09% of mortality has been reported and all the CIFN reactions were predictable. In the 19 CIFN patients, there has no significant effect of prophylaxis to prevent the FN.
Clinical trial identification
Legal entity responsible for the study
All authors have declared no conflicts of interest.